Corrigendum: Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor.
更正：短期和長期接觸自助餐飲食對食物攝取和由胰高血糖素樣肽-1受體介導的白色脂肪組織脂解的影響。
Front Endocrinol (Lausanne) 2024-02-27
Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
更正：GLP-1RAs導致藥物停用的胃腸不良反應：系統回顧和網絡荟萃分析。
Front Endocrinol (Lausanne) 2023-10-30
這是修正過的具有 DOI 編號為 10.3389/fendo.2023.1149328 的文章。
PubMedDOI
Correction to "Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes" <i>(J Clin Endo Metab Case Reports.</i> 2023; 1(1): 10.1210/jcemcr/luac017).
「糖尿病患者中使用 Semaglutide 的 GLP-1 受體激動劑治療」<i>（J Clin Endo Metab Case Reports.</i> 2023; 1(1): 10.1210/jcemcr/luac017）修正。
JCEM Case Rep 2023-11-01
Correction to "Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes".
「糖尿病患者中使用 Semaglutide 的胰高血糖素樣肽-1 受體激動劑治療」的更正。
JCEM Case Rep 2023-11-01
Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
更正：關於 tirzepatide（胰臟炎和膽囊或膽道疾病）在第2型糖尿病和肥胖症中的安全問題：系統性回顧和荟萃分析。
Front Endocrinol (Lausanne) 2024-03-29
這篇修正後的文章有 DOI 編號：10.3389/fendo.2023.1214334。
PubMedDOI
Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024;47(Suppl. 1):S158-S178.
更正。9. 糖尿病治療的藥物治療方法：2024年糖尿病護理標準。Diabetes Care 2024;47(Suppl. 1):S158-S178.
Diabetes Care 2024-05-02
Corrigendum: Dynamic evolution of left ventricular strain and microvascular perfusion assessed by speckle tracking echocardiography and myocardial contrast echocardiography in diabetic rats: effect of dapagliflozin.
更正：糖尿病大鼠左心室應變和微血管灌注的動態演變，通過斑點追蹤超聲心動圖和心肌對比超聲心動圖評估：dapagliflozin 的影響。
Front Cardiovasc Med 2024-07-24
Corrigendum to "The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 9, September 2023, Pages 1831-1840].
對於「代謝症候群、高過濾率與一般人群長期GFR下降之間的關聯」的更正 [<i>Kidney International Reports</i> 第8卷，第9期，2023年9月，頁1831-1840]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1267 EMPAGLIFLOZIN IMPROVES VITALITY AND PROTECT FROM ADVANCED GLYCATION END PRODUCTS IN ENDOTHELIAL CELLS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S637].
對於「WCN24-1267 EMPAGLIFLOZIN 改善活力並保護內皮細胞免受高級糖化終產物的影響」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S637頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 6, Issue 4, April 2021, Pages 1183-1188].
對於「Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy」的更正 [<i>Kidney International Reports</i> 第6卷，第4期，2021年4月，頁1183-1188]。
Kidney Int Rep 2024-07-31